CO2023000594A2 - Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-ilo - Google Patents
Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-iloInfo
- Publication number
- CO2023000594A2 CO2023000594A2 CONC2023/0000594A CO2023000594A CO2023000594A2 CO 2023000594 A2 CO2023000594 A2 CO 2023000594A2 CO 2023000594 A CO2023000594 A CO 2023000594A CO 2023000594 A2 CO2023000594 A2 CO 2023000594A2
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- oxadiazol
- formulation
- methyl
- low
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona un compuesto de Fórmula I: , o una sal farmacéuticamente aceptable de este, en donde el compuesto de Fórmula I, o una sal farmacéuticamente aceptable de este, se administra por vía oral con una dosis total del compuesto de 0,1 mg/día a 5 mg/día, y es útil para tratar una enfermedad neurodegenerativa, incluidas las tauopatías neurodegenerativas, como la enfermedad de Alzheimer, la demencia frontotemporal, el síndrome corticobasilar y la parálisis supranuclear progresiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055362P | 2020-07-23 | 2020-07-23 | |
| PCT/US2021/042877 WO2022020663A1 (en) | 2020-07-23 | 2021-07-23 | Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023000594A2 true CO2023000594A2 (es) | 2023-01-26 |
Family
ID=77338898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0000594A CO2023000594A2 (es) | 2020-07-23 | 2023-01-19 | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-ilo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230338349A1 (es) |
| EP (1) | EP4185291A1 (es) |
| JP (1) | JP2023535034A (es) |
| KR (1) | KR20230043905A (es) |
| CN (1) | CN116323604A (es) |
| AR (1) | AR123031A1 (es) |
| AU (1) | AU2021312894A1 (es) |
| BR (1) | BR112023000975A2 (es) |
| CA (1) | CA3186808A1 (es) |
| CL (1) | CL2023000194A1 (es) |
| CO (1) | CO2023000594A2 (es) |
| DO (1) | DOP2023000009A (es) |
| EC (1) | ECSP23005057A (es) |
| IL (1) | IL300023A (es) |
| MX (1) | MX2023000993A (es) |
| PE (1) | PE20231031A1 (es) |
| TW (1) | TW202220650A (es) |
| WO (1) | WO2022020663A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240145486A (ko) | 2022-02-03 | 2024-10-07 | 일라이 릴리 앤드 캄파니 | 알츠하이머병을 진단 및 치료하기 위한 국소 타우 영상화 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110747A1 (es) * | 2017-01-27 | 2019-05-02 | Lilly Co Eli | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo |
| CN112543648A (zh) * | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
-
2021
- 2021-07-21 TW TW110126729A patent/TW202220650A/zh unknown
- 2021-07-21 AR ARP210102050A patent/AR123031A1/es unknown
- 2021-07-23 CN CN202180063288.5A patent/CN116323604A/zh active Pending
- 2021-07-23 AU AU2021312894A patent/AU2021312894A1/en active Pending
- 2021-07-23 US US18/005,245 patent/US20230338349A1/en active Pending
- 2021-07-23 JP JP2023504346A patent/JP2023535034A/ja active Pending
- 2021-07-23 EP EP21755253.8A patent/EP4185291A1/en active Pending
- 2021-07-23 MX MX2023000993A patent/MX2023000993A/es unknown
- 2021-07-23 WO PCT/US2021/042877 patent/WO2022020663A1/en active Application Filing
- 2021-07-23 CA CA3186808A patent/CA3186808A1/en active Pending
- 2021-07-23 IL IL300023A patent/IL300023A/en unknown
- 2021-07-23 PE PE2023000107A patent/PE20231031A1/es unknown
- 2021-07-23 KR KR1020237005839A patent/KR20230043905A/ko active Search and Examination
- 2021-07-23 BR BR112023000975A patent/BR112023000975A2/pt unknown
-
2023
- 2023-01-19 CO CONC2023/0000594A patent/CO2023000594A2/es unknown
- 2023-01-19 CL CL2023000194A patent/CL2023000194A1/es unknown
- 2023-01-20 DO DO2023000009A patent/DOP2023000009A/es unknown
- 2023-01-23 EC ECSENADI20235057A patent/ECSP23005057A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000009A (es) | 2023-02-15 |
| IL300023A (en) | 2023-03-01 |
| US20230338349A1 (en) | 2023-10-26 |
| ECSP23005057A (es) | 2023-02-28 |
| WO2022020663A1 (en) | 2022-01-27 |
| CA3186808A1 (en) | 2022-01-27 |
| CN116323604A (zh) | 2023-06-23 |
| PE20231031A1 (es) | 2023-07-10 |
| JP2023535034A (ja) | 2023-08-15 |
| MX2023000993A (es) | 2023-03-01 |
| EP4185291A1 (en) | 2023-05-31 |
| AR123031A1 (es) | 2022-10-26 |
| TW202220650A (zh) | 2022-06-01 |
| AU2021312894A1 (en) | 2023-02-23 |
| BR112023000975A2 (pt) | 2023-02-07 |
| KR20230043905A (ko) | 2023-03-31 |
| CL2023000194A1 (es) | 2023-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| CL2023000167A1 (es) | Péptidos funcionalizados como agentes antivirales | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| CO2023000594A2 (es) | Régimen de dosis baja y formulación de un compuesto 5-metil-1,2,4- oxadiazol-3-ilo | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| UY39510A (es) | Compuestos macrocíclicos y métodos para usarlos | |
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| JPWO2020145331A5 (es) | ||
| AR109760A1 (es) | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson | |
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| CO2024000761A2 (es) | Antagonistas del receptor muscarínico 4 y métodos de uso | |
| AR121671A1 (es) | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el ácido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxílico o una sal farmacéutica del mismo | |
| PE20240241A1 (es) | Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilo | |
| ES2280150T1 (es) | Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma. |